MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    Masticatory function evaluation methods in movement disorders

    Y. Navarrete Cortés, P. Castelo, L. Feitosa, G. Azevedo Diaféria, A. Said, C. Ribeiro Neves, O. Barsottini, S. Bommarito (São Paulo, Brazil)

    Objective: To characterize masticatory function in individuals with Parkinson's Disease (PD) and Spinocerebellar Ataxia (SCA3) regarding the orofacial myofunctional condition (OMES-E), the masticatory performance and…
  • 2024 International Congress

    Impact of Community Boxing Program on Non-motor Symptoms in Individuals with Parkinson’s Disease

    M. Braitsch, S. Shearin, R. Querry, E. Perez (Richardson, USA)

    Objective: The purpose of this intervention was to assess the impact of boxing on non-motor symptoms (NMS) in PD. Background: ​​​​​​For persons with Parkinson’s Disease…
  • 2024 International Congress

    Incidence of Depression in the Caregivers of Parkinson’s Disease Patients

    S. Soleimani, M. Salari, F. Hojjati Pour (Tehran, Islamic Republic of Iran)

    Objective: To evaluate the impact of caring for individuals with Parkinson's disease on caregivers' social activities and mental health, and to assess depression and quality…
  • 2024 International Congress

    Palliative and end-of-life care in Parkinson’s disease : French patients’ perceptions and knowledge

    M. Auffret, L. Cronier, G. Robert, M. Béreau, M. Giffard, M. Vérin (Rennes, France)

    Objective: (1) Assess patients' perceptions and knowledge of palliative and end-of-life care in PD; (2) evaluate (i) whether patients discuss these topics with healthcare professionals and/or…
  • 2024 International Congress

    A Prospective, Multicenter, Single-Arm Feasibility Study Examining ECAP-Controlled, Closed-Loop Spinal Cord Stimulation for Parkinson’s Disease (eCAP-PD): Technical and Design Considerations

    L. Verhagen, T. Virmani, M. Pourfar, C. Hess, J. Rosenow, E. Petersen, A. Mogilner, J. Karl, N. Shetty (Chicago, USA)

    Objective: Conduct a prospective feasibility study to determine the effects of ECAP-controlled closed-loop spinal cord stimulation (SCS) on motor symptoms in Parkinson’s disease (PD) patients.…
  • 2024 International Congress

    Efficacy of Opicapone and Levodopa with Different Levodopa Daily Doses in Parkinson’s Disease Patients with Early Motor Fluctuations: Findings from the Korean ADOPTION Study

    J. Lee, J. Ferreira, H. Ma, J. Rocha, B. Jeon (Seoul, Republic of Korea)

    Objective: To evaluate the effect of opicapone (OPC) 50 mg versus an additional levodopa (L-DOPA) dose of 100 mg in patients with Parkinson’s disease (PD)…
  • 2024 International Congress

    Assessing a Video Based Approach at Measuring Parkinson’s Disease Severity – A Validation Study

    BP. Bridges (St. John's, Canada)

    Objective: To validate the Parkinson’s remote interactive monitoring system’s assessment of Parkinson’s disease compared to a clinical assessment completed by a movement disorder specialist. Background:…
  • 2024 International Congress

    Remote recruitment of hyposmic participants identifies biomarkers related to neuronal alpha-synuclein disease

    E. Brown, A. Siderowf, T. Simuni, T. Sherer, M. Brumm, C. Caspell-Garcia, R. Kurth, C. Gochanour, M. Marshall, M. Korell, C. Stanley, L. Concha, C. Soto, K. Marek, C. Tanner (San Francisco, USA)

    Objective: To evaluate the proportion of people with dopaminergic deficit and positive alpha-synuclein seed amplification assay (aSyn SAA) among a remotely identified group of hyposmic…
  • 2024 International Congress

    Safety and tolerability of opicapone in Parkinson’s Disease: from early-stage (EPSILON study) to late-stage (BIPARK studies)

    G. Cordeiro, I. Peixoto, H. Gama, L. Magalhães, J. Moreira, J-F. Rocha, J. Holenz (Trofa, Portugal)

    Objective: To compare the safety and tolerability of once-daily opicapone (OPC) 50mg as add-on to stable levodopa/dopa decarboxylase inhibitor (L-DOPA/DDCI) therapy in patients from early…
  • 2024 International Congress

    Five-Year Changes in MDS-UPDRS-III after Light Treatment (Photobiomodulation)

    B. Bicknell, S. Tilley, G. Herkes, A. Liebert (, Westmead, Australia)

    Objective: To determine the effectiveness of photobiomodulation (light therapy) on MDS-UPDRS-III scores over a five-year period Background: As a progressive neurodegenerative disease, worsening of motor…
  • « Previous Page
  • 1
  • …
  • 59
  • 60
  • 61
  • 62
  • 63
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley